PCSK9 inhibitors may reduce atherosclerotic plaque according to a study presented at the European Society of Cardiology Congress. Researchers found that PCSK9 inhibitors can create "an anti-inflammatory state which may directly influence atherosclerosis and cardiovascular disease," said lead author Johan Frostegard.
Study: PCSK9 inhibitors may reduce atherosclerotic plaque
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.